In recent months much controversy has focused on interpretations of new data concerning
the safety and efficacy of Haemophilus influenzae type b vaccines. 1-3 These controversies …

The conjugate Haemophilus influenzae type b (Hib) vaccines are safe and far more
immunogenic among infants and young children than is the unconjugated H. influenzae type …

Abstract The Committee on Infectious Diseases of the American Academy of Pediatrics
attempts to provide'guidelines that complement the physician's clinical judgment and …

In April 1985, the US FDA licensed Haemophilus influenzae type b polysaccharide vaccine
to protect against invasive disease caused by H influenzae type b. Shortly thereafter, both …

In December 1987 the first Haemophilus influenzae type b polysaccharide-protein conjugate
vaccine was licensed for use in the United States., 2 The vaccine is composed of the Hib …

This statement is provided in response to the December 1990 US Food and Drug
Administration (FDA) approval of labeling for a second Haemophilus influenzae type b …

Although there has been controversy about the protective efficacy of the Haemophilus b
polysaccharide vaccine, this controversy may become moot because of the licensure of …

April marked the second anniversary of licensure of the first vaccine intended to prevent
Haemophilus influenzae type b infection." To date more than 10 million doses of vaccine …

The efficacy of the HbOC conjugate Haemophilus influenzae type b vaccine was evaluated
in a study population of 61 080 infants in the Northern California Kaiser Permanente Medical …

Abstract Between February 1988 and June 1990, the safety, immunogenicity, and efficacy of
Haemophilus influenzae type b (Hib) oligosaccharide conjugate (HbOC) vaccine was …